Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10982252 | 0.93 | CYP4F2 (0.50) | CYP4F2CYP4A11TDP1ALDH1A1HRH3 | |
| SCHEMBL1587126 | 0.86 | MEN1 (0.45) | CYP4F2CYP4A11TDP1ALDH1A1LMNA | |
| SCHEMBL10399807 | 0.86 | CYP4F2 (0.62) | CYP4F2CYP4A11TDP1HRH3F2RL1 | |
| SCHEMBL7420345 | 0.86 | CYP4F2 (0.49) | CYP4F2CYP4A11TDP1ALDH1A1LMNA | |
| SCHEMBL15608606 | 0.84 | CYP4F2 (0.44) | CYP4F2CYP4A11TDP1HRH3F2RL1 | |
| SCHEMBL9326099 | 0.84 | CYP4F2 (0.44) | CYP4F2CYP4A11TDP1ALDH1A1TAAR1 | |
| SCHEMBL7420342 | 0.84 | CYP4F2 (0.44) | CYP4F2CYP4A11TDP1ALDH1A1HRH3 | |
| SCHEMBL17066813 | 0.84 | CYP4F2 (0.44) | CYP4F2CYP4A11TDP1HRH3CYP4Z1 | |
| SCHEMBL9792904 | 0.84 | CYP4F2 (0.44) | CYP4F2CYP4A11TDP1ALDH1A1HRH3 | |
| SCHEMBL7322522 | 0.84 | CYP4F2 (0.44) | CYP4F2CYP4A11TDP1HRH3F2RL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147365-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-05-20 | — | — | US | disclosed |
| US-10450277-B2 | Analogs of fexaramine and methods of making and using | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190084939-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2019-03-21 | — | — | US | disclosed |
| US-20100189795-A1 | CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS | NEOCUTIS S.A. (CH) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147365-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | FXR2, FXR1, SLC10A2 | CYP4F2 124/4885CYP4A11 320/4885TDP1 4075/4885 |
| US-10450277-B2 | Analogs of fexaramine and methods of making and using | FXR2, FXR1, SLC10A2 | CYP4F2 124/4885CYP4A11 320/4885TDP1 4075/4885 |
| US-20100189795-A1 | CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS | S100A4, TYR, CACYBP | CYP4F2 4061/4885CYP4A11 3745/4885TDP1 2370/4885 |
| US-20190084939-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | FXR2, FXR1, SLC10A2 | CYP4F2 124/4885CYP4A11 320/4885TDP1 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.